Helicobacter pylori vaccine: Mucosal adjuvant & delivery systems

Indian Journal of Medical Research

Volumn 130, Issue 2, 2009, Pages 115-124

  Sijun, Hu ^a   Yong, Xie ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

Adjuvant; Delivery systems; Helicobacter pylori; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; BACTERIAL VECTOR; CAGA PROTEIN; CATALASE; CHITOSAN; CHOLERA TOXIN; CPG OLIGODEOXYNUCLEOTIDE; CXCL1 CHEMOKINE; ESCHERICHIA COLI ENTEROTOXIN; ESCHERICHIA COLI HEAT LABILE ENTEROTOXIN K63; ESCHERICHIA COLI HEAT LABILE ENTEROTOXIN R192G; FREUND ADJUVANT; HELICOBACTER PYLORI VACCINE; HERBACEOUS AGENT; LIPOSOME; LIVE ATTENUATED SALMONELLA TYPHIMURIUM VECTOR; MODIFIED POLIO VIRUS VECTOR; MUTANT PROTEIN; POLYGLACTIN; RECOMBINANT HEAT SHOCK PROTEIN 60 VACCINE; UNCLASSIFIED DRUG; UREASE; UREASE A; UREASE B; VACUOLATING TOXIN; VIRUS VECTOR;

ABDOMINAL CRAMP; ADJUVANT THERAPY; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG SCREENING; EXPRESSION VECTOR; FUSION GENE; HELICOBACTER INFECTION; HUMAN; MUCOSA; NONHUMAN; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; CHOLERA TOXIN; DRUG CARRIERS; ENTEROTOXINS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MUCOUS MEMBRANE;

EID: 70349524750     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Hussell T, Isaacson PG, Crabtree JE, Spencer J. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 1993; 342: 571-4.
2. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342: 575-7.
3. IARC. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the evaluation carcinogenic risk to human. Lyon, June 7-14, 1994. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 1-241.
4. Goodman KJ, Cockburn M. The role of epidemiology in understanding the health effects of Helicobacter pylori. Epidemiology 2001; 12: 266-71.
5. Bulajic M, Stimec B, Milicevic M, Loehr M, Mueller P, Boricic I, et al. Modalities of testing Helicobacter pylori in patients with nonmalignant bile duct diseases. World J Gastroenterol 2002; 8: 301-4.
6. Xu CD, Chen SN, Jiang SH, Xu JY. Seroepidemiology of Helicobacter pylori infection among asymptomatic Chinese children. World J Gastroenterol 2000; 6: 759-61.
7. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, Elomar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht III Consensus Report. Gut 2007; 56: 772-81.
8. Mégraud F. Basis for the management of drug-resistant Helicobacter pylori infection. Drugs 2004; 64: 1893-904.
9. Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ 2000; 321: 659-64.
10. Ruggiero P, Peppoloni S, Rappuoli R, Giudice, GD. The quest for a vaccine against Helicobacter pylori: how to move from mouse to man? Microbes Infect 2003; 5: 749-56.
11. Ferrero RL, Thiberge JM, Kansau I, Wuscher N, Huerre M, Labigne A. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA 1995; 92: 6499-503.
12. Michetti P, Corthésy-Theulaz I, Davin C, Haas R, Vaney AC, Heitz M, et al. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology 1994; 107: 1002-11.
13. Stein M, Rappuoli R, Covacci A. Tyrosine phosphorylation of the Helicobacter pylori CagA antigen after cag-driven host cell translocation. Prco Natl Acard Sci USA 2000; 97: 1263-8.
14. Satin B, Del Giudice G, Della Bianca V, Dusi S, Laudanna C, Tonello F, et al. The neutrophi-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med 2000; 191: 1467-76.
15. Lundgren A, Trollmo C, Edebo A, Svennerholm AM, Lundin BS. Helicobacter pylori-specific CD4(+) T cells home to and accumulate in the human Helicobacter pylori-infected gastric mucosa. Infect Immun 2005; 73: 5612-9.
16. Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998; 113: 401-6.
17. Yamamoto T, Kita M, Ohno T, Iwakura Y, Sekikawa K, Imanishi J. Role of tumor necrosis factor-alpha and interferon-gamma in Helicobacter pylori infection. Microbiol Immunol 2004; 48: 647-54.
18. Del Giudice G, Covacci A, Telford JL, Montecucco C, Rappuoli R. The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol 2001; 19: 523-63.
19. Kotloff KL, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker RI. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun 2001; 69: 3581-90.
20. Michetti P, Kreiss C, Kotloff KL, Porta N, Blanco JL, Bachmann D, et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999; 116: 804-12.
21. Ermak TH, Giannasca PJ, Nichols R, Myers GA, Nedrud J, Weltzin R, et al. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med 1998; 188: 2277-88.
22. Blanchard TG, Czinn SJ, Redline RW, Sigmund N, Harriman G, Nedrud JG. Antibody-independent protective mucosal immunity to gastric helicobacter infection in mice. Cell Immunol 1999; 191: 74-80.
23. Sutton P, Wilson J, Kosaka T, Wolowczuk I, Lee A. Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies. Immunol Cell Biol 2000; 78: 28-30.
24. Saldinger PF, Porta N, Launois P, Louis JA, Waanders GA, Bouzourene H, et al. Immunization of BALB/c mice with Helicobacter urease B induces a T helper 2 response absent in Helicobacter infection. Gastroenterology 1998; 115: 891-7.
25. Garhart CA, Nedrud JG, Heinzel FP, Sigmund NE, Czinn SJ. Vaccine-induced protection against Helicobacter pylori in mice lacking both antibodies and interleukin-4. Infect Immun 2003; 71: 3628-33.
26. Akhiani AA, Pappo J, Kabok Z, Schon K, Gao W, Franzen LE, et al. Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J Immunol 2002; 169: 6977-84.
27. Akhiani AA, Schon K, Lycke N. Vaccine-induced immunity against Helicobacter pylori infection is impaired in IL-18-deficient mice. J Immunol 2004; 173: 3348-56.
28. Miller CJ, McChesney M, Moore PF. Langerhans cells, macrophages and lymphocyte subsets in the cervix and vagina of rhesus macaques. Lab Invest 1992; 67: 628-34.
29. Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol 1987; 7: 265-76.
30. Babiuk LA, Pontarollo R, Babiuk S, Loehr B, van Drunen Littel-van den Hurk S. Induction of immune responses by DNA vaccines in large animals. Vaccine 2003; 21: 649-58.
31. Gupta RK, Siber GR. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 1995; 13: 1263-76.
32. Glenny AT, Pope CG, Waddington H, Wallace U. Immunological notes XVII to XXIV. J Pathol 1926; 29: 31-40.
33. Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharm Biotechnol 1995; 6: 141-228.
34. Minoura T, Kato S, Otsu S, Fujioka T, Iinuma K, Nishizono A. Childhood Helicobacter pylori infection in a murine model: maternal transmission and eradication by systemic immunization using bacterial antigen-aluminium hydroxide. Clin Exp Immunol 2003; 134: 32-7.
35. Eisenberg JC, Czinn SJ, Garhart CA, Redline RW, Bartholomae WC, Gottwein JM, et al. Protective efficacy of anti-Helicobacter pylori immunity following systemic immunization of neonatal mice. Infect Immun 2003; 71: 1820-7.
36. Pappo J, Thomas WD Jr, Kabok Z, Taylor NS, Murphy JC, Fox JG. Effect of oral immunization with recombinant urease on murine Helicobacter felis gastritis. Infect Immun 1995; 63: 1246-52.
37. Ruiz-Bustos E, Sierra-Beltran A, Romero MJ, Rodriguez-Jaramillo C, Ascencio F. Protection of BALB/c mice against experimental Helicobacter pylori infection by oral immunisation with H.pylori heparan sulphate-binding proteins coupled to cholera toxin beta-subunit. J Med Microbiol 2000; 49: 535-41.
38. Losonsky GA, Kotloff KL, Walker RI. B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HWC) vaccine and LT(R192G) in H.pylori seronegative individuals. Vaccine 2003; 21: 562-5.
39. Lee CK, Soike K, Hill J, Georgakopoulos K, Tibbitts T, Ingrassia J, et al. Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. Vaccine 1999; 17: 1493-505.
40. Sommer F, Wilken H, Faller G, Lohoff M. Systemic Th1 immunization of mice against Helicobacter pylori infection with CpG oligodeoxynucleotides as adjuvants does not protect from infection but enhances gastritis. Infect Immun 2004; 72: 1029-35.
41. Shi T, Liu WZ, Gao F, Shi GY, Xiao SD. Intranasal CpG-oligodeoxynucleotide is a potent adjuvant of vaccine against Helicobacter pylori, and T helper 1 type response and interferon-gamma correlate with the protection. Helicobacter 2005; 10: 71-9.
42. Gottwein JM, Blanchard TG, Targoni OS, Eisenberg JC, Zagorski BM, Redline RW, et al. Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund's adjuvant by systemic immunization. J Infect Dis 2001; 184: 308-14.
43. Gherardi RK, Coquet M, Cherin P, Belec L, Moretto P, Dreyfus PA, et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 2001; 124: 1821-31.
44. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004; 82: 488-96.
45. Di Tommaso A, Saletti G, Pizza M, Rappuoli R, Dougan G, Abrignani S, et al. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect Immun 1996; 64: 974-9.
46. Radcliff FJ, Hazell SL, Kolesnikow T, Doidge C, Lee A. Catalase, a novel antigen for Helicobacter pylori vaccination. Infect Immun 1997; 65: 4668-74.
47. Dubois A, Lee CK, Fiala N, Kleanthous H, Mehlman PT, Monath T. Immunization against natural Helicobacter pylori infection in nonhuman primates. Infect Immun 1998; 66: 4340-6.
48. Bagley KC, Abdelwahab SF, Tuskan RG, Lewis GK. An enzymatically active a domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants. Infect Immun 2003; 71: 6850-6.
49. Petrovska L, Lopes L, Simmons CP, Pizza M, Dougan G, Chain BM. Modulation of dendritic cell endocytosis and antigen processing pathways by Escherichia coli heat-labile enterotoxin and mutant derivatives. Vaccine 2003; 21: 1445-54.
50. Gagliardi MC, Sallusto F, Marinaro M, Vendetti S, Riccomi A, De Magistris MT. Effects of the adjuvant cholera toxin on dendritic cells: stimulatory and inhibitory signals that result in the amplification of immune responses. Int J Med Microbiol 2002; 291: 571-5.
51. Marinaro M, Staats HF, Hiroi T, Jackson RJ, Coste M, Boyaka PN, et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol 1995; 155: 4621-9.
52. Takahashi I, Marinaro M, Kiyono H, Jackson RJ, Nakagawa I, Fujihashi K, et al. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis 1996; 173: 627-35.
53. D'Elios MM, Manghetti M, Almerigogna F, Amedei A, Costa F, Burroni D, et al. Different cytokine profile and antigenspecificity repertoire in Helicobacter pylori-specific T cell clones from the antrum of chronic gastritis patients with or without peptic ulcer. Eur J Immunol 1997; 27: 1751-5.
54. Guy B, Hessler C, Fourage S, Haensler J, Vialon-Lafay E, Rokbi B, et al. Systemic immunization with urease protects mice against Helicobacter pylori infection. Vaccine 1998; 16: 850-6.
55. Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002; 20: 2431-8.
56. van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000; 165: 4778-82.
57. Ghiara P, Rossi M, Marchetti M, Di Tommaso A, Vindigni C, Ciampolini F, et al. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect Immun 1997; 65: 4996-5002.
58. Giuliani MM, Del Giudice G, Giannelli V, Dougan G, Douce G, Rappuoli R, et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med 1998; 187: 1123-32.
59. Ryan EJ, McNeela E, Pizza M, Rappuoli R, O'Neill L, Mills KH. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity. J Immunol 2000; 165: 5750-9.
60. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-60.
61. Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M, et al. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol 2001; 167: 4878-86.
62. Prinz C, Hafsi N, Voland P. Helicobacter pylori virulence factors and the host immune response: implications for therapeutic vaccination. Trends Microbiol 2003; 11: 134-8.
63. Wagner H. Toll meets bacterial CpG-DNA. Immunity 2001; 14: 499-502.
64. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 1995; 270: 404-10.
65. Jones DH, McBride BW, Thornton C, O'Hagan DT, Robinson A, Farrar GH. Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B.pertussis respiratory infection. Infect Immun 1996; 64: 489-94.
66. Shahin R, Leef M, Eldridge J, Hudson M, Gilley R. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-coglycolide) microspheres. Infect Immun 1995; 63: 1195-200.
67. Cahill ES, O'Hagan DT, Illum L, Barnard A, Mills KH, Redhead K. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. Vaccine 1995; 13: 455-62.
68. de Haan A, Tomee JF, Huchshorn JP, Wilschut J. Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice. Vaccine 1995; 13: 1320-4.
69. Nencioni L, Pizza M, Bugnoli M, De Magistris T, Di Tommaso A, Giovannoni F, et al. Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough. Infect Immun 1990; 58: 1308-15.
70. Xie Y, Zhou NJ, Gong YF, Zhou XJ, Chen J, Hu SJ, et al. Th immune response induced by H. pylori vaccine with chitosan as adjuvant and its relation to immune protection. World J Gastroenterol 2007; 13: 1547-53.
71. Novaka MJ, Smythiesb LE, McPhersona SA, Smith PD, Morrowa CD. Poliovirus replicons encoding the B subunit of Helicobacter pylori urease elicit a Th1 associated immune response. Vaccine 1999; 17: 2384-91.
72. Tinsley-Bown AM, Fretwell R, Dowsett AB, Davis SL, Farrar GH. Formulation of poly(D,L-lactic-co-glycolic acid) microparticles for rapid plasmid DNA delivery. J Control Release 2000; 66: 229-41.
73. Almeida AJ, Alpar HO. Nasal delivery of vaccines. J Drug Target 1996; 3: 455-67.
74. Beier R, Gebert A. Kinetics of particle uptake in the domes of Peyer's patches. Am J Physiol 1998; 275: 130-7.
75. Eldridge JH, Gilley RM, Staas JK, Moldoveanu Z, Meulbroek JA, Tice TR. Biodegradable microspheres: vaccine delivery system for oral immunization. Curr Top Microbiol Immunol 1989; 146: 59-66.
76. Kim SY, Doh HJ, Ahn JS, Ha YJ, Jang MH, Chung SI, et al. Induction of Induction of mucosal and systemic immune response by oral immunization with H. pylori lysates encapsulated in poly(D,L-lactide-co-glycolide) microparticles. Vaccine 1999; 17: 607-16.
77. Jani C, McCarthy E, Fluorence T. Nanosphere and microsphere uptake via Peyer's patch: observation of the rate of uptake in the rat after a single oral dose. Int J Pharm 1992; 86: 239-46.
78. Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 1994; 11: 1358-61.
79. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan for mucosal vaccination. Adv Drug Deliv Rev 2001; 52: 139-44.
80. Lee KY, Kwon IC, Kim YH, Jo WH, Jeong SY. Preparation of chitosan self-aggregates as a gene delivery system. J Control Release 1998; 51: 213-20.
81. Leong KW, Mao HQ, Truong-Le VL, Roy K, Walsh SM, August JT. DNA-polycation nanospheres as non-viral gene delivery vehicles. J Control Release 1998; 53: 183-93.
82. Wimer-Mackin S, Hinchcliffe M, Petrie CR, Warwood SJ, Tino WT, Williams MS, et al. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. Vaccine 2006; 24: 3953-63.
83. van der Lubben IM, Kersten G, Fretz MM, Beuvery C, Coos Verhoef J, Junginger HE. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 2003; 21: 1400-8.
84. Bacon A, Makin J, Sizer PJ, Jabbal-Gill I, Hinchcliffe M, Illum L, et al. Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun 2000; 68: 764-70.
85. Bivas-Benita M, Laloup M, Versteyhe S, Dewit J, De Braekeleer J, Jongert E, et al. Generation of Toxoplasma gondii GRA1 protein and DNA vaccine loaded chitosan particles: preparation, characterization, and preliminary in vivo studies. Int J Pharm 2003; 266: 17-27.
86. Xie Y, Zhou NJ, Gong YF, Chen J, Zhou XJ, Lu NH, et al. Th immune response induced by H.pylori therapeutic vaccine with chitosan as adjuvant. J Gastroenterol Hepatol 2007; 22: A239.
87. Xie Y, Gong YF, Zhou NJ, Chen J, Zhou XJ, Lu NH, et al. The role of local immune response in gastric mucosa in the protection induced by Helicobacter pylori vaccine with chitosan as adjuvant. Zhonghua Yi Xue Za Zhi 2005; 85: 2629-35.
88. Sabin AB, Boulger LR. History of Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand 1973; 1: 115-8.
89. Smythiesa LE, Novakb MJ, Waitesc KB, Lindsey JR, Morrow CD, Smitha PD. Poliovirus replicons encoding the B subunit of Helicobacter pylori urease protect mice against H.pylori infection. Vaccine 2005; 23: 901-9.
90. Hopkins S, Kraehenbuhl JP, Schödel F, Potts A, Peterson D, de Grandi P, et al. A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization. Infect Immun 1995; 63: 3279-86.
91. Galen JE, Gomez-Duarte OG, Losonsky GA, Halpern JL, Lauderbaugh CS, Kaintuck S, et al. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens. Vaccine 1997; 15: 700-8.
92. Gilman RH, Hornick RB Woodward WE. Immunity in typhoid fever: evaluation of Ty21 a. An epimeraseless mutant of S. typhi as a live oral vaccine. J Infect Dis 1977; 136: 717-23.
93. Wahdan MH, Serie C, Cerisier Y, Sallam S, Germanier R. A controlled field trial of line Salmonella typhi Ty2la vaccine strain against typhoid: three years results. J Infect Dis 1984; 145: 292-5.
94. Metzger WG, Mansouri E, Kronawitter M, Diescher S, Soerensen M, Hurwitz R, et al. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2004; 22: 2273-7.
95. Bai Y, Zhang YL, Wang JD, Zhang ZS, Zhou DY. Construction of attenuated Salmonella typhimurium strain expressing Helicobacter pylori conservative region of adhesin antigen and its immunogenicity. World J Gastroenterol 2004; 10: 2498-502.
96. Corthésy-Theulaz IE, Hopkins S, Bachmann D, Saldinger PF, Porta N, Haas R, et al. Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium phoPc expressing urease A and B subunits. Infect Immun 1998; 66: 581-6.
97. Liu X, Hu J, Zhang X, Fan D. Oral immunization of mice with attenuated Salmonella typhimurium expressing Helicobacter pylori urease B subunit. Chin Med J (Engl) 2002; 115: 1513-6.
98. Angelakopoulos H, Hohmann EL. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar Typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect Immun 2000; 68: 2135-41.
99. Gómez-Duarte OG, Lucas B, Yan ZX, Panthel K, Haas R, Meyer TF. Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vaccine 1998; 16: 460-71.
100. Bumann D, Metzger WG, Mansouri E, Palme O, Wendland M, Hurwitz R, et al. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2001; 20: 845-52.
101. DiPetrillo MD, Tibbetts T, Kleanthous H, Killeen KP, Hohmann EL. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 1999; 18: 449-59.
102. Liu XF, Hu JL, Quan QZ, Sun ZQ, Wang YJ, Qi F. Systemic immune responses to oral administration of recombinant attenuated Salmonella typhimurium expressing Helicobacter pylori urease in mice. World J Gastroenterol 2005; 11: 2154-6.
103. Xu C, Li ZS, Du YQ, Gong YF, Yang H, Sun B, et al. Construction of recombinant attenuated Salmonella typhimurium DNA vaccine expressing H. pylori ureB and IL-2. World J Gastroenterol 2007; 13: 939-44.
104. Chen M, Chen J, Liao W, Zhu S, Yu J, Leung WK, et al. Immunization with attenuated Salmonella typhimurium producing catalase in protection against gastric Helicobacter pylori infection in mice. Helicobacter 2003; 8: 613-25.
105. Gentschev I, Dietrich G, Spreng S, Kolb-Mäurer A, Brinkmann V, Grode L, et al. Recombinant attenuated bacteria for the delivery of subunit vaccines. Vaccine 2001; 19: 2621-8.
106. Dietrich G, Kolb-Mäurer A, Spreng S, Schartl M, Goebel W, Gentschev I. Gram-positive and Gram-negative bacteria as carrier systems for DNA vaccines. Vaccine 2001; 19: 2506-12.
107. Curtiss R 3rd, Galan JE, Nakayama K, Kelly SM. Stabilization of recombinant avirulent vaccine strains in vivo. Res Microbiol 1990; 141: 797-805.
108. Xie Y, Liu DS, Zhou NJ, Cao J, Lu NH. Construction and identification of recombinant attenuated salmonella typhimurium expressing BabA/UreI fusion protein of Helicobacter pylori. J Gastroenterol Hepatol 2007; 22: A189.
109. Miller SI, Kukral AM, Mekalanos JJ. A two-component regulatory system (phoP phoQ) controls Salmonella typhimurium virulence. Proc Natl Acad Sci USA 1989; 86: 5054-8.
110. Nardelli-Haefliger D, Kraehenbuhl JP, Curtiss R 3rd, Schodel F, Potts A, Kelly S, et al. Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain. Infect Immun 1996; 64: 5219-24.
111. Nardelli-Haefliger D, Roden RB, Benyacoub J, Sahli R, Kraehenbuhl JP, Schiller JT, et al. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun 1997; 65: 3328-36.
112. Hohmann EL, Oletta CA, Killeen KP, Miller SI. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis 1996; 173: 1408-14.
113. Gómez-Duarte OG, Bumann D, Meyer TF. The attenuated Salmonella vaccine approach for the control of Helicobacter pylori-related diseases. Vaccine 1999; 17: 1667-73.
114. Huang W, Bai Y, Wang JD, Wu JB, Li GF, Zhang WM, et al. Preparation oral liposome-encapsulated recombinant Helicobacter pylori heat shock protein 60 vaccine for prevention of Hp infection. Di Yi Jun Yi Da Xue Xue Bao 2005; 25: 531-4.
115. Szostak MP, Hensel A, Eko FO, Klein R, Auer T, Mader H, et al. Bacterial ghosts: non-living candidate vaccines. J Biotechnol 1996; 44: 161-70.
116. Bernhardt TG, Roof WD, Young R. Genetic evidence that the bacteriophage phi X174 lysis protein inhibits cell wall synthesis. Proc Natl Acad Sci USA 2000; 97: 4297-302.
117. Panthel K, Jechlinger W, Matis A, Rohde M, Szostak M, Lubitz W, et al. Generation of Helicobacter pylori ghosts by PhiX protein E-mediated inactivation and their evaluation as vaccine candidates. Infect Immun 2003; 71: 109-16.
118. Gu Q, Han N, Liu J, Zhu M. Expression of Helicobacter pylori urease subunit B gene in transgenic rice. Biotechnol Lett 2006; 28: 1661-6.
119. Nilsson CL, Larsson T, Gustafsson E, Karlsson KA, Davidsson P. Identification of protein vaccine candidates from Helicobacter pylori using a preparative two-dimensional electrophoretic procedure and mass spectrometry. Anal Chem 2000; 72: 2148-53.
120. Haas G, Karaali G, Ebermayer K, Metzger WG, Lamer S, Zimny-Arndt U, et al. Immunoproteomics of Helicobacter pylori infection and relation to gastric disease. Proteomics 2002; 2: 313-24.
121. Smith TG, Lim JM, Weinberg MV, Wells L, Hoover TR. Direct analysis of the extracellular proteome from two strains of Helicobacter pylori. Proteomics 2007; 7: 2240-5.
122. Franco AT, Friedman DB, Nagy TA, Romero-Gallo J, Krishna U, Kendall A, et al. Delineation of a carcinogenic Helicobacter pylori proteome. Mol Cell Proteomics 2009; 8: 1947-58.